<object id="q8oyw"></object>
<sup id="q8oyw"><option id="q8oyw"></option></sup><object id="q8oyw"><tr id="q8oyw"></tr></object>
<center id="q8oyw"><center id="q8oyw"></center></center>
<object id="q8oyw"></object>
<acronym id="q8oyw"><div id="q8oyw"></div></acronym>
<object id="q8oyw"></object>
<acronym id="q8oyw"><wbr id="q8oyw"></wbr></acronym>
<object id="q8oyw"></object>
咨詢熱線

15000266580

當前位置:首頁 >產(chǎn)品中心>細胞庫>人腫瘤細胞、癌細胞>SK-OV-3人卵巢癌細胞

人卵巢癌細胞

簡要描述:HTB-77 SK-OV-3 人卵巢癌細胞,
ATCC 細胞|細胞系|細胞株|腫瘤細胞|細胞,細胞庫管理規(guī)范,
提供的細胞株背景清楚,提供參考文獻和培養(yǎng)條件

  • 產(chǎn)品型號:SK-OV-3
  • 廠商性質(zhì):生產(chǎn)廠家
  • 更新時間:2024-11-12
  • 訪  問  量:1889

產(chǎn)品分類

Product Category

相關(guān)文章

Related Articles

詳細介紹

HTB-77 SK-OV-3 人卵巢癌細胞

ATCC® Number: HTB-77™ Price: $272.00

Designations: SK-OV-3 [SKOV-3]

Depositors: G Trempe, LJ Old

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens (human)

Morphology: epithelial

HTB-77 SK-OV-3 人卵巢癌細胞

Source: Organ: ovary

Disease: adenocarcinoma

Derived from metastatic site: ascites

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.


Restrictions: The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; (212) 717-3439.

Isolation: Isolation date: 1973

Applications: transfection host (Nucleofection technology from Lonza

Roche FuGENE® Transfection Reagents)

Tumorigenic: Yes

Antigen Expression: Blood Type B; Rh+

DNA Profile (STR): Amelogenin: X

CSF1PO: 11

D13S317: 8,11

D16S539: 12

D5S818: 11

D7S820: 13,14

THO1: 9,9.3

TPOX: 8,11

vWA: 17,18

Cytogenetic Analysis: This is a hypodiploid human cell line. The modal chromosome number was 43, occurring in 63.3% of cells. The range was 42 to 45. The rate of higher ploidies was 32%. The del(1)(q21), der(13)t(1;?;13) (q11;?;q34), der(11)t(11;?) (q12), del(10)(q22) and 3 other marker chromosomes were common to most cells, and 3 others were found only in some cells. One N11 had the HSR segment from p11 to the distal end. The normal N10, N12, N15, N17 and N19 were absent. Others were either single or paired. There were from 1 to 6 rearranged and unassignable chromosomes. The X chromosome was either single or paired.

Isoenzymes: AK-1, 1

ES-D, 1

G6PD, B

GLO-I, 1-2

Me-2, 1

PGM1, 1-2

PGM3, 1

Age: 64 years

Gender: female

Ethnicity: Caucasian

Comments: SK-OV-3 cells are resistant to tumor necrosis factor and to several cytotoxic drugs including diphtheria toxin, cis-platinum and adriamycin.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Temperature: 37.0°C

Subculturing: Protocol:

1.Remove and discard culture medium.

2.Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.

3.Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).

Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.

4.Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.

5.Add appropriate aliquots of the cell suspension to new culture vessels.

6.Incubate cultures at 37°C.

Subc*tion Ratio: A subc*tion ratio of 1:2 to 1:6 is recommended

Medium Renewal: 2 to 3 times per week

Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO

Storage temperature: liquid nitrogen vapor phase

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2007

recommended serum:ATCC 30-2020

References: 21869: . Human tumor cells in vitro. New York: Plenum Press; 1975.

22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871

22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080

23103: Morimoto H, et al. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res. 53: 2591-2596, 1993. PubMed: 7684321

23478: Morimoto H, et al. Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin- mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J. Immunol. 147: 2609-2616, 1991. PubMed: 1918981

32281: Zhang X, et al. Microfilament depletion and circumvention of multiple drug resistance by sphinxolides. Cancer Res. 57: 3751-3758, 1997. PubMed: 9288783

32456: Clinton GM, et al. Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc. Natl. Acad. Sci. USA 93: 316-320, 1996. PubMed: 8552629

32530: Zhang X, Smith CD. Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance. Mol. Pharmacol. 49: 288-294, 1996. PubMed: 8632761

90272: Wiechen K, et al. Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells. Br. J. Cancer 81: 790-795, 1999. PubMed: 10555747

90273: Yu D, et al. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 53: 891-898, 1993. PubMed: 8094034

90274: Karlan BY, et al. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gyn. Onc. 53: 70-77, 1994. PubMed: 7909787



HTB-77 SK-OV-3




















產(chǎn)品咨詢

留言框

  • 產(chǎn)品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細地址:

  • 補充說明:

  • 驗證碼:

    請輸入計算結(jié)果(填寫阿拉伯數(shù)字),如:三加四=7
聯(lián)系方式

郵箱:xiangfbio@163.com

地址:上海市虹口區(qū)四平路710號7層

咨詢熱線

400-821-8510

(周一至周日9:00- 19:00)

在線咨詢
  • 掃一掃 微信咨詢

Copyright©2024 上海復(fù)祥生物科技有限公司 All Right Reserved    備案號:滬ICP備10013034號-2     sitemap.xml
技術(shù)支持:化工儀器網(wǎng)    管理登陸
<object id="q8oyw"></object>
<sup id="q8oyw"><option id="q8oyw"></option></sup><object id="q8oyw"><tr id="q8oyw"></tr></object>
<center id="q8oyw"><center id="q8oyw"></center></center>
<object id="q8oyw"></object>
<acronym id="q8oyw"><div id="q8oyw"></div></acronym>
<object id="q8oyw"></object>
<acronym id="q8oyw"><wbr id="q8oyw"></wbr></acronym>
<object id="q8oyw"></object>
威宁| 淳化县| 开平市| 上思县| 明溪县| 湟源县| 肥东县| 藁城市| 阳江市| 秦安县| 汽车| 巫溪县| 望江县| 盐亭县| 察哈| 吴忠市| 资中县| 漳浦县| 神池县| 西畴县| 华蓥市| 天镇县| 道真| 怀柔区| 龙口市| 永济市| 平塘县| 镇远县| 武乡县| 疏勒县| 永登县| 呼玛县| 交口县| 和顺县| 鹤壁市| 胶州市| 宁乡县| 临海市| 灌云县| 广宗县| 叙永县| http://444 http://444 http://444 http://444 http://444 http://444